Insider Selling: Histogenics Corp (HSGX) Major Shareholder Sells $42,806.00 in Stock

Histogenics Corp (NASDAQ:HSGX) major shareholder Randal J. Kirk sold 251,800 shares of the firm’s stock in a transaction that occurred on Friday, January 11th. The shares were sold at an average price of $0.17, for a total transaction of $42,806.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Shares of HSGX opened at $0.15 on Friday. The firm has a market cap of $8.87 million, a PE ratio of -0.16 and a beta of 2.15. Histogenics Corp has a 12-month low of $0.08 and a 12-month high of $3.35.

Histogenics (NASDAQ:HSGX) last issued its earnings results on Thursday, November 8th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.05). As a group, sell-side analysts predict that Histogenics Corp will post -0.04 EPS for the current fiscal year.

Several equities research analysts have weighed in on the stock. Zacks Investment Research raised shares of Histogenics from a “hold” rating to a “buy” rating and set a $0.25 price target for the company in a research note on Tuesday. HC Wainwright set a $1.00 target price on shares of Histogenics and gave the stock a “buy” rating in a report on Friday, November 9th. Finally, ValuEngine raised shares of Histogenics from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $2.44.

Several institutional investors and hedge funds have recently modified their holdings of HSGX. Virtu Financial LLC bought a new stake in shares of Histogenics in the third quarter valued at about $117,000. Renaissance Technologies LLC raised its holdings in shares of Histogenics by 6.1% in the second quarter. Renaissance Technologies LLC now owns 384,329 shares of the biotechnology company’s stock valued at $961,000 after acquiring an additional 22,133 shares in the last quarter. Finally, BlackRock Inc. raised its holdings in shares of Histogenics by 72.0% in the second quarter. BlackRock Inc. now owns 54,753 shares of the biotechnology company’s stock valued at $137,000 after acquiring an additional 22,927 shares in the last quarter. 16.85% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Insider Selling: Histogenics Corp (HSGX) Major Shareholder Sells $42,806.00 in Stock” was first posted by WKRB News and is the property of of WKRB News. If you are reading this report on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The original version of this report can be read at https://www.wkrb13.com/2019/01/18/insider-selling-histogenics-corp-hsgx-major-shareholder-sells-42806-00-in-stock.html.

About Histogenics

Histogenics Corp. engages in the development, marketing, and commercialization of musculoskeletal medicine. Its regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives, and growth factors to provide solutions that can be utilized individually and in concert to treat musculoskeletal-related conditions.

Featured Story: What is the quiet period?

Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply